Acer Therapeutics Inc. (ACER) Analysts See $-0.69 EPS as of May, 11

April 17, 2018 - By Russell Jones

Earnings report for Acer Therapeutics Inc. (NASDAQ:ACER) is anticipated On May, 11., as reported by Faxor. Analysts have anticipation on stock’s earnings per share of $-0.69. That’s up 44.35 % from last year’s $-1.24 earnings per share. After $-0.63 EPS report last quarter, Wall Street now predicts 9.52 % negative EPS growth of Acer Therapeutics Inc.. On during the last trading session the stock increased $0.22 or 1.14%, reaching $19.49.Acer Therapeutics Inc. has volume of 8,775 shares. Since April 17, 2017 ACER has risen 126.38% and is uptrending. ACER outperformed by 114.83% the S&P 500.

Acer Therapeutics Inc. develops therapies for the treatment of serious ultra-rare diseases with critical unmet medical needs.The company has $146.13 million market cap. The firm offers Celiprolol for vascular ehlers-danlos syndrome and ACER-001 for maple syrup urine disease .Last it reported negative earnings. It also offers advancing ACER-001 for the treatment of urea cycle disorders (UCD).

Acer Therapeutics Inc. (NASDAQ:ACER) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: